Oakland, California 94609

  • Sickle Cell Disease


The purpose of this study is to determine whether simvastatin is effective in reducing the frequency and intensity of vaso-occlusive pain episodes in patients with sickle cell disease.

Study summary:

Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive episodes and a chronic inflammatory state leading to progressive multi-organ injury. The pathophysiology of SCD is related to endothelial dysfunction driven largely by impaired nitric oxide (NO) homeostasis and chronic inflammation. Through multiple mechanisms, including upregulation of NO, statins have been shown to confer protection from endothelial injury, independent of their cholesterol-lowering properties. By inhibiting inflammation and several common pathways leading to vascular damage,simvastatin may help prevent the acute and chronic complications of SCD. The objective of this study is to determine whether our preliminary results showing simvastatin-associated reductions in plasma markers of vascular injury will translate into a reduction in vaso-occlusive pain episodes in patients with SCD. A web-based, smartphone-accessible electronic pain diary will be used to monitor frequency and intensity of vaso-occlusive pain in SCD patients treated with a single daily dose of simvastatin.


Inclusion Criteria: - Sickle cell disease (HbSS or S/β0 thalassemia) - ≥ 3 vaso-occlusive pain episodes in the year prior to enrollment - Age ≥ 10 years - Weight > 30 kg Exclusion Criteria: - Creatine kinase (CK) >1X UNL - Total cholesterol < 90 mg/dL, or TG <30mg/dL - Renal dysfunction (Creatinine > 1.5X UNL) - Hepatic dysfunction (ALT > 2X UNL) - Treatment with drugs having known metabolic interactions with statins (e.g.cytochrome P450 3A4 metabolism or amiodarone) within the past 30 days - Vaso-occlusive pain requiring hospitalization within past 30 days - RBC transfusion within the past 30 days - Pregnancy/lactation - Musculoskeletal disorder associated with an elevated CK level - Past or present history of substance abuse (alcohol, cocaine, amphetamines, heroin, PCP) - Chronic pain caused by avascular necrosis of the bone (AVN) or leg ulcers, and pain due to trauma or causes other than SCD. - Major cognitive or neurological impairments that may hamper the ability to use the smartphone or complete the eDiary in this study



Primary Contact:

Principal Investigator
Carolyn Hoppe, MD
Children's Hospital & Research Center Oakland

Carolyn Hoppe, M.D.
Email: choppe@mail.cho.org

Backup Contact:

Email: lstyles@chori.org
Lori Styles, M.D.

Location Contact:

Oakland, California 94609
United States

Carolyn Hoppe, M.D.
Phone: 510-428-3193
Email: choppe@mail.cho.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.